Trial Profile
Phase IB Study of Paclitaxel + Carboplatin With AVB-S6-500 in Women With Stage III or IV Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Receiving Neoadjuvant Chemotherapy
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase I
Latest Information Update: 30 Sep 2021
Price :
$35
*
At a glance
- Drugs Batiraxcept (Primary) ; Carboplatin; Paclitaxel
- Indications Adenocarcinoma; Carcinoma; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Adverse reactions
- 23 Sep 2021 Status changed from not yet recruiting to withdrawn prior to enrolment and reason the study was stopped as the trial may move forward as an NCI-sponsored trial and not an investigator initiated trial.
- 18 Jan 2021 Planned End Date changed from 28 Feb 2028 to 31 Aug 2029.
- 18 Jan 2021 Planned primary completion date changed from 28 Feb 2023 to 31 Aug 2024.